Janssen Business Development

Identifying Pathways to Better Health
Through Collaboration

Learn more

About Us

Johnson & Johnson Innovation | Janssen Business Development seeks to identify collaborative opportunities that will create transformative value for our partners and the world.

Driving Collaborative Innovation to Accelerate Breakthroughs

If you are with an established pharmaceutical company, mid-sized to large biotechnology company, seek a collaboration or merger & acquisition discussions, or have a compound that has shown proof of concept in humans, make the connection with Johnson & Johnson Innovation, Janssen Business Development.

Janssen Business Development is very active in acquiring assets, companies, and technologies as well as entering into strategic collaborations, including joint ventures, developments, and commercial partnerships.


  • Patrick Verheyen
    Global Head, Janssen Business Development
  • Shamin Dewsi
    Office Leader - Toronto
  • Micheal J. Grissinger
    Corporate Development Group for Johnson & Johnson’s Pharmaceutical Business
  • Denise McGinn
    Vice President and Head of Cardiovascular/Metabolism (CVM) Business Development and Licensing
  • Lucinda Warren
    Vice President, Alliance Management
  • Debi Watson
    Head of the Oncology Licensing Team
  • Close

    Patrick Verheyen

    Global Head, Janssen Business Development

    Patrick is Global Head, Janssen Business Development. In this role, Patrick leads the business development organization to identify, execute, integrate and manage global licensing, mergers & acquisitions (M&A), divestiture and out-licensing deals for the Janssen Pharmaceutical Companies of Johnson & Johnson. Patrick assumed this role in April 2015.

    Prior to this, Patrick helped design and launch Johnson & Johnson Innovation and was Head of Johnson & Johnson Innovation, London. This Innovation strategy has delivered a robust early-stage portfolio and has helped earn Johnson & Johnson a reputation as a preferred partner with external innovators, entrepreneurs, and academic institutions.

    Patrick joined Johnson & Johnson in 1986 at Janssen Pharmaceuticals in Beerse, Belgium. Previously, he was Vice President, New Ventures, Pharmaceuticals, where he led an agile and diverse team who facilitated divestitures, established strategic collaborations, and identified investments that provided Janssen with access to external innovation and early product flow. Patrick also served as Vice President, M&A, where he facilitated strategic collaborations and acquisitions including Crucell, Elan, and Cougar Biotechnology, and established spin-out companies, including Movetis. Patrick has provided expertise on most of the major M&A deals in the biotech, specialty pharmaceutical and large capital space, and assessed various risk sharing and funding arrangements with Clinical Research Organizations, private equity groups, and government institutions.

    Patrick studied bioengineering at the University of Leuven, Flanders, Belgium. 

  • Close

    Shamin Dewsi

    Office Leader - Toronto

  • Close

    Micheal J. Grissinger

    Corporate Development Group for Johnson & Johnson’s Pharmaceutical Business

    Mike serves on the Senior Leadership Team for Johnson & Johnson’s Pharmaceutical Business Development Organization.  In this role, Mike is accountable for the business development activities of Johnson & Johnson’s Immunology therapeutic area franchise, as well as heading the Mergers & Acquisition Operations team, and the Pharmaceuticals Divestiture Group. Previously, Mike led the Worldwide Pharmaceutical Licensing Team, including search, evaluation and transactions for licensing deals across all therapeutic areas of interest to Johnson & Johnson.

    Mike joined Johnson & Johnson in 1996 as Director of Business Development for Johnson & Johnson Health Care Systems and was appointed Vice President of Business Development in 1998.  In 2000, Mike joined the Pharmaceuticals Group as Vice President, Mergers & Acquisitions.  In 2002, he was promoted to the Management Board of Ortho-McNeil Pharmaceutical as Vice President Corporate Development, where he was responsible for pharmaceutical licensing.  He was subsequently appointed to the Pharmaceutical North America Leadership Team and the Worldwide CNS/Internal Medicine Franchise Board.

    Prior to joining Johnson & Johnson, Mike spent twenty years in the healthcare industry with Ciba-Geigy, SmithKline, and Upjohn.  He began his career as a chemist with The Upjohn Company.  Mike has worked in finance, held various marketing positions including Group Product Director for Ciba’s Consumer Pharmaceutical Division, and has completed a wide variety of business development, licensing, and acquisition assignments spanning Consumer, Healthcare Services, and Pharmaceutical businesses.

    Mike received his BS in Chemistry from Juniata College and his MBA in Finance from Temple University.

  • Close

    Denise McGinn

    Vice President and Head of Cardiovascular/Metabolism (CVM) Business Development and Licensing

    Denise serves as Vice President and Head of Cardiovascular/Metabolism (CVM) Business Development and Licensing. Her team has executed research collaborations, development deals, and commercial arrangements in diabetes, obesity, diabetic nephropathy, heart failure, and thrombosis. In addition, Denise is accountable for supporting commercial stage deals for the Janssen Operating Company in Japan (JPKK).

    Prior to her current position, Denise held Vice President of Business Development and Licensing positions for the Infectious Disease Area, the Biotechnology, Immunology and Oncology Business Unit, and the Janssen Pharmaceuticals Asia Pacific, Japan, and Latin America region.

    Denise joined J&J from Centocor which was acquired by J&J in late 1999. At Centocor, she began her career in discovery research, identifying and creating human monoclonal antibodies to treat various disease states. Denise was promoted into various other functions at Centocor, including Project Management, ultimately heading up that group, and Marketing, and created the initial Strategic Marketing team at Centocor before being recruited into Janssen Business Development.

    Denise holds a BS degree in Microbiology from Pennsylvania State University.

  • Close

    Lucinda Warren

    Vice President, Alliance Management

    Lucinda Warren, VP Business Development, Neuroscience
    Johnson & Johnson Innovation / Janssen Business Development.

    Lucinda heads the Neuroscience Business Development Team which includes scientific finding, licensing transactions, mergers, acquisition, out licensing and alliance management. 

    With over 23 years of broad industry experience, Lucinda began her Pharma career in Canada.   In 1999 she joined the Johnson & Johnson Family of Companies and has held various USA and Global roles of increasing responsibilities, including Sales, Marketing, New Product Development, Alliance Management, and Business Development Leadership.   Lucinda has been responsibility for the leadership and oversight of some of Janssen’s longest and largest global commercial alliances in addition to leading the global integration of Johnson & Johnson’s single largest asset REMICADE®, back into the organization in 2011. 

    Just prior to joining the Janssen Development Leadership Team, Lucinda led the Immunology Business Unit in Australia, returning to the USA in 2014 as VP Alliance Management, Janssen, responsible for leading the Pharmaceutical portfolio of collaborations.

    Lucinda earned her BSc from the University of Alberta.

  • Close

    Debi Watson

    Head of the Oncology Licensing Team

    Debi is the head of the Oncology Licensing Team which handles all oncology transactions with established companies and all clinical stage opportunities. Prior to this role, Debi was the Vice President of the Infectious Disease Licensing Team. She has held a variety of positions within Business Development and has worked across several business units and therapeutic areas.

    Debi has facilitated important strategic collaborations which include the Geron License Agreement for imetelstat, the MarcroGenics License Agreement for MGD011, License Agreements with Gilead for the J&J HIV business, and the Divestment & Option Agreement with Furiex.

    Prior to joining the Business Development Team, Debi held several marketing roles in the J&J Neuroscience group working on established brands and new product launches.

    Debi joined the Johnson & Johnson Family of Companies in 1991 at Janssen Pharmaceuticals in Titusville, NJ. She earned a BA from the University of Connecticut.


The Janssen Business Development team focuses on mid- and late-stage collaborations with established pharmaceutical and larger biotechnology companies to accelerate breakthrough innovation to solve unmet medical needs and create real value in Janssen’s five defined therapeutic areas.

Strong Science Is at the Heart of Everything We Do

Our approach meaningfully integrates deal makers with science leaders from the very beginning. Having a clear and focused strategy that is grounded in the science allows the Janssen Business Development team to shape better deals and achieve in-market impact faster by understanding where each partner can add value.

Proven Two-Way Value Can Be Found in Every Partnership

The Janssen Business Development team has a proven, positive track record of deal performance. Our thoughtful approach to risk-taking includes spending the time to understand the needs of our partners so that deals can be structured to maximize value for all parties.

Dynamic Approaches Pave the Way to Success

Since no two deals are exactly alike, the Janssen Business Development team employs a flexible and adaptive approach to tailor the optimal deal structure to each unique partner opportunity. Our direct access to decision makers within Johnson & Johnson allows for creative and timely problem solving to optimize success.

True Collaboration Drives All of Our Actions

We are focused on genuine collaborations and seek out relationships with partners who desire transparency and openness, which we believe leads to new ideas and better solutions. Our goal is to form active partnerships where we can bring the full strength of Johnson & Johnson to bear to create a lasting and valuable relationship.

Focus Areas

Our Pharmaceuticals business is divided into five core areas, Cardiovascular & Metabolism; Immunology; Infectious Diseases & Vaccines; Neuroscience; and Oncology. Janssen Business Development seeks innovation across all of these areas where there is significant unmet patient need. 

  • Type 2 Diabetes
    Cardiovascular and Metabolism
    Cardiovascular and Metabolism
  • Psoriasis, Inflammatory Bowel Disease, Rheumatoid Arthritis
  • Respiratory Infections, Hepatitis
    Diseases and Vaccines
    Infectious Diseases and Vaccines
  • Mood Disorders, Alzheimer's Disease
  • Prostate Cancer, Lung Cancer, Hematologic Malignancies


  • Johnson & Johnson Innovation and Janssen Pharmaceuticals, Inc. Announce Agreement with Chia Tai Tianqing Pharmaceutical Group Co., Ltd. to ...

    NEW BRUNSWICK, N.J. (January 7, 2016)

    Johnson & Johnson Innovation and Janssen Pharmaceuticals, Inc. today announced an exclusive license agreement with Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CTTQ), a Chinese domestic pharmaceutical company and subsidiary of Sino Biopharma, Ltd. focused on liver diseases, to develop, manufacture and commercialize, outside of China, undisclosed immune-modulating agents to treat human diseases, including curative treatment of chronic Hepatitis B virus (HBV) infection.

  • Johnson & Johnson Announces Completion of Novira Therapeutics, Inc. Acquisition

    December 4, 2015 | New Brunswick, NJ

    Johnson & Johnson (NYSE: JNJ) today announced the completion of the acquisition of Novira Therapeutics, Inc., a privately held, clinical-stage biopharmaceutical company developing innovative therapies for curative treatment of chronic hepatitis B virus (HBV) infection. The transaction was originally announced on November 4, 2015. Financial terms of the transaction have not been disclosed.


  • Collaborating to Study New Treatment for Insomnia Related to Depression

    February 3, 2015

    One of the promising scientific collaborations in our neuroscience pipeline is with Minerva Neurosciences, focusing on MIN-202 – a selective orexin-2 antagonist being studied for the treatment of insomnia and potentially other disorders associated with sleep disorders such as major depressive disorder, an area of strategic focus for Janssen.

Contact us

Make the Connection

We look forward to our first discussion. If you would like to discuss a collaboration,
simply click the contact us button which will connect you to our Idea Portal and a member of our team will contact you.

Johan Verbeeck, DVM, MsC
Head, External Partnering Strategy
Johnson & Johnson Innovation,
Janssen Business Development
Email: jverbee2@ITS.JNJ.com
Telephone: +1 908 331 9507



Neomed (Montreal)
7171 Frederick-Banting
Montreal, Quebec, CANADA H4S 1Z9
(514) 367 1212
Your web browser is out of date. For the most optimal experience, please upgrade to the newest version of IE. Thank You.